Literature DB >> 31188771

Neoadjuvant and Adjuvant Treatment with Denosumab in Aggressive Giant-cell Tumor of Bone in the Proximal Fibula: a Case Report.

Violeta V Marinova1, Svetoslav A Slavchev2, Kircho D Patrikov2, Petya M Tsenova1, Georgi P Georgiev3.   

Abstract

Giant cell tumor of bone is a histologically benign but locally aggressive osteolytic lesion, capable of spreading 'benign' metastases mainly to the lungs. Since its description as a separate entity, surgery has been the mainstay of treatment. Recently, target therapy has been introduced using denosumab - an inhibitor antibody for the receptor activator of nuclear factor kappa B ligand with dramatic eff ect on the natural course of the tumor. Herein, we report a rare case of an aggressive stage 3 giant cell tumor of bone of the proximal fibula that was successfully downstaged using neoadjuvant denosumab treatment and then treated by surgical excision followed by adjuvant target therapy. The clinical characteristics and treatment modalities of giant cell tumor of bone, the indications for target therapy, therapy response, and histological changes are also briefly discussed.

Entities:  

Keywords:  RANK ligand; denosumab; giant cell tumor of bone; neoadjuvant therapy; osteoclasts

Mesh:

Substances:

Year:  2018        PMID: 31188771     DOI: 10.2478/folmed-2018-0067

Source DB:  PubMed          Journal:  Folia Med (Plovdiv)        ISSN: 0204-8043


  3 in total

1.  En Bloc Resection of Giant Cell Tumor following Neoadjuvant Denosumab: A Case Report and Review of the Literature.

Authors:  Sarah C Tepper; Ari M Spellman; Charles A Gusho; Alan T Blank
Journal:  Orthop Rev (Pavia)       Date:  2022-05-31

2.  Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial.

Authors:  Jiaji Yue; Wei Sun; Shenglong Li
Journal:  J Bone Oncol       Date:  2022-06-24       Impact factor: 4.491

3.  Denosumab for Effective Tumor Size Reduction in Patients With Giant Cell Tumors of the Bone: A Systematic Review and Meta-Analysis.

Authors:  Josef Yayan
Journal:  Cancer Control       Date:  2020 Jul-Aug       Impact factor: 3.302

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.